Why is AeroVironment stock rallying today?

AeroVironment reported FY2027 Q1 adjusted EPS of $0.59, nearly double the $0.30 consensus estimate, while record revenue of $480.5 million exceeded the $459.9 million forecast. Funded backlog rose 37% year over year to a record $1.5 billion, supported by demand for uncrewed aircraft systems and Switchblade precision-strike munitions. The company reaffirmed FY2027 revenue guidance of $2.125-$2.225 billion and adjusted EPS guidance of $3.02-$3.34; shares rose 3.9% after hours after falling 4.7% during regular trading.

Analysis

The key signal is not the one-quarter beat but the reduction in a near-term execution-risk premium after estimates were cut into the print. AVAV’s order book supports revenue visibility, yet unchanged full-year guidance implies management is preserving room for program timing, production ramp costs, or mix-related margin pressure; the market should not mechanically annualize the quarterly EPS result. The next 1-3 months hinge on whether sell-side FY2027 estimates rise toward the upper end of guidance rather than merely reversing last week’s cuts.

AVAV is unusually leveraged to expendable precision-strike and small-UAS replenishment demand, making it a more direct beneficiary of sustained procurement urgency than diversified primes such as LMT and NOC. Second-order beneficiaries include propulsion and electronics suppliers, but the more investable relative read-through is likely KTOS, where investors may re-rate tactical-drone demand if AVAV’s backlog conversion confirms that procurement is moving from experimentation to scaled orders. Conversely, a shift toward lower-cost, commodity drone platforms or delayed appropriations would pressure AVAV’s premium multiple first.

Consensus may be underestimating the asymmetry created by heavily de-risked expectations, but it may also be overlooking valuation risk: a backlog-driven rerating requires evidence that funded awards convert into revenue without gross-margin dilution. Watch the next quarterly guide, segment margin trajectory, and evidence of customer concentration or contract timing. A guidance increase or backlog-to-revenue conversion above plan would validate a 6-18 month compounding thesis; margin erosion, a book-to-bill slowdown, or a federal budget disruption would falsify it quickly.

Key Decisions for Investors

• Tactically accumulate AVAV over the next 1-5 sessions only if the regular-session move holds above the post-earnings opening range; target a 10-15% rerating over 1-3 months as estimate cuts reverse, with a stop on a close below the pre-earnings low. Do not chase a gap materially above that range without confirming volume.
• Run a 3-6 month relative-value pair: long AVAV / short ITA in equal beta-adjusted dollars. This isolates the higher-growth small-UAS and munition exposure from broad defense-budget and rate risk; exit if AVAV’s next report shows segment-margin deterioration or no upward revision to full-year outlook.
• Put KTOS on an earnings/read-through alert rather than initiating immediately. A confirmed acceleration in AVAV order conversion would support a sympathy rerating in KTOS; require KTOS guidance or funded-order evidence before acting, since the competitive overlap does not establish direct revenue transfer.
• Monitor FY2027 consensus EPS and revenue revisions weekly. If estimates fail to move higher within 2-3 weeks despite the report, treat the reaction as short-covering rather than a durable fundamental inflection and reduce tactical exposure.